We present a case of severe thromboembolic pulmonary hypertension in a patient with history of recurrent deep vein thrombosis and pulmonary restrictive disease due to pulmonary and vertebral tuberculosis in young adulthood. He was considered not eligible in the National Program for Primary Pulmonary Hypertension, being referred for thoracic surgery, but he was considered unfit for thrombendarterectomy. Despite guidelines, we administered him specific medical therapy (phosphodiesterase-5 inhibitors and endothelin receptor antagonists). His clinical evolution was satisfactory, with increasing effort tolerance and decreasing need for ambulatory oxigenotherapy.
Case Report
We present the case of a 64 years old male patient, with history of right femuro-popliteal deep vein thrombosis and recurrent pulmonary thromboembolism. He experienced his first pulmonary embolism 3 years ago and repeated a new episode after about 6 months, when we estimated at echocardiography a value of the systolic pressure in the pulmonary artery of 70 mmHg, indicating severe pulmonary hypertension.
Due to the recurrence of the pulmonary thromboembolism, at that time we performed investigations aiming to highlight some of the associated thromboembolic risk factors: the thrombophilic profile was normal, tumoral markers, abdominal and pelvic CT were negative for malignant diseases. He had no family antecedents of clinical manifestations of thromboembolic diseases.
After a period of about 6 months with minimal symptoms under oral anticoagulant and diuretic treatment, the patient returns in the Cardiology Clinic with decompensated right heart failure (inferior limbs edema, hepatomegaly with turgid jugulars), respiratory insufficiency (spontaneous Sp02 = 88%) and systemic hypotension (blood pressure = 90/60mmHg, equal on both arms). Clinical examination also revealed severe decreased body mass index (16,6kg/m2) and diastolic murmur in the pulmonary area. On ultrasound we detected worsened pulmonary pressures (systolic pressure in the pulmonary artery = 120 mmHg) and marked expansion of right cavities with systolic dysfunction of the right ventricle. Biological data showed effi cient anticoagulation with INR 2,7 and atrial natriuretic peptide highly increased.
The trans-thoracic echocardiography showed a severe dilatation of right cavities, right atrium diameter 72 mm, telediastolic area of the right atrium 37cmp, right ventricle with telediastolic diameter 58 mm, hypertrophy of the free wall of the right ventricle = 14 mm, tricuspid severe regurgitation, severe systolic dysfunction of the right ventricle with the systolic excursion of the tricuspid ring plan = 13 mm, gradient between right ventricle and right atrium=92mmHg, inferior vena cava dilated with inspiratory collapse < 50% expansion of pulmonary trunk 40 mm and the possible image of thrombus in right pulmonary branch of the pulmonary artery; the left ventricle with reduced dimensions as compared to the right. Computed thoracic angio-tomography with contrast substance (angio-CT) presents thrombosis at the origin of the right pulmonary artery with extension on the right medium lumbar artery to the periphery, with possible pulmonary infarction within the right inferior lobe and left petrifi ed pleurisy.
Given these data, the following diagnosis was established:
1. Severe chronic thromboembolic pulmonary hypertension, with partially obstructive thrombosis within the right pulmonary artery 2. Congestive cardiac failure, functional class IV 3. Severe functional tricuspidian insuffi ciency 4. Moderate pulmonary insuffi ciency 5. Pleurisy and left pachypleuritis 6. Deep venous thrombosis at the level of the right inferior limb in antecedents. We considered our patient having indication for pulmonary thromboendarterectomy, so we performed coronarography and cardiac right catheterization. The cardiac right catheterization confi rms the existence of increased pressures in the pulmonary circulation (pulmonary artery systolic pressure = 110mmHg, medium pulmonary artery pressure = 60mmHg) with increased total pulmonary resistance and diminished cardiac index 1,35 l/min/m². The coronarography showed normal epicardial coronary arteries and excluded other congenital defects.
Discussions
Current data [1] suggest that our patient was a potential candidate for the thrombendarterectomy surgery, so we sent him towards a reference tertiary Cardio-Vascular Diseases Centre. Pre-surgical reevaluation and the pneumology investigations eff ectuated within this center have argued the terms of benefi t and prognosis of this patient.
The patient presents negative preoperative prognostic factors with increased risk of hemodynamic instability [2] : severe systolic dysfunction of the right ventricle (ejection fraction of the right ventricle <20%), increased natriuretic atrial peptide (BNP), distal micro-vascular disorder, respiratory severe restriction with severely low gas transfer at the level of the alveolar-capillary membrane. The combination of persistent macro-vascular obstruction (the thrombus in the pulmonary artery) with the development of the micro-vascular arteriopathy explains the clinical aspect of severe pulmonary hypertension. Increased pulmonary vascular resistances, invasively determined, are considered an independent mortality risk factor [3] , and in the case of our patient the presence of elevated pulmonary vascular resistances >600 dynes/cm 3 in association with the macrovascular affection has made him an ineligible candidate for the pulmonary thromboendarterectomy, estimating a higher postoperative risk of mortality and the persistence of the post-thromboendarterectomy pulmonary hypertension. Considering these data, and in particular the micro-vascular disease, we choose the specific combination therapy [3, 4] with inhibitors of Phosphodiesterase-5 (Sildenafil 20mg x3/day) and endothelin receptor antagonists (Bosentan oral 62, 5mg x2/day) along with standard medical treatment with diuretics, oral anticoagulant and hyperbaric medicine. The option for the specific therapy for arterial pulmonary hypertension was argued by the physiopathologic aspects of micro-vascular affectation from the thromboembolic pulmonary hypertension. The main physiopathologic mechanism in the thromboembolic pulmonary hypertension is not represented by the formation of thrombus, but rather from its poor resolution; the pulmonary embolism as a single or repetitive episode is the triggering event followed by a vascular remodeling [5] . In time, there occurs a distal micro-vascular injury similar to that of an idiopathic pulmonary hypertension characterized by plexiform lesions contributing to the pressure load of the right heart chambers and the progression of pulmonary hypertension [6, 7] .
Therapeutic alternatives available at this moment are represented by the atrial balloon septostomy, as a "bridge" intervention to the cardiopulmonary transplant [8] , but considering the favorable evolution of the patient under the specific combination therapy with Phosphodiesterase-5 inhibitors and endothelin receptors antagonists, with the clinic and hemodynamic improvement of pulmonary pressures, the interventional treatment to realize the inter-atrial communication was temporized, the patient being included on the list for cardio-pulmonary transplant.
Case particularity
A particularity of the presented case is the fact that, on repeating computed thoracic angiotomography with contrast substance after 6 months of medical treatment, patient presents elements of a favorable prognosis, i.e. the development of systemic collaterals and dilation of systemic arteries as response to the pulmonary hypo-perfusion (decreased pulmonary flow, hypoxemia, fibrosis and inflammation). The favorable answer to the specific combined therapy, together with the development of multiple collaterals constitutes the arguments for the favorable clinical evolution of our patient, with an obvious improvement of the right cardiac failure phenomena.
